In accordance with a New York Occasions report, Johnson & Johnson has stopped producing its single-dose COVID-19 vaccination.
Final yr, the pharmaceutical firm quietly stopped manufacturing on the Leiden, Netherlands plant that produced vaccines. This caught some clients off guard, particularly these from growing nations preferring single-dose J&J medicine to two-dose options.
Johnson & Johnson as an alternative used the plant to develop a probably extra profitable drug that would shield in opposition to a unrelated respiratory virus. In accordance with the report.
Though the plant is anticipated to renew manufacturing of COVID-19 vaccines, it's not clear when.
J&J did not touch upon the stories of the plant closing, however acknowledged in an announcement to CBS Information that they'd "hundreds of thousands of doses" of their COVID-19 vaccine and have been persevering with to meet their contractual obligations to the African Union.
The vaccine of alternative in poorer nations
Janssen Biotech, a Janssen Biotech subsidiary of Johnson & Johnson is offering the Janssen COVID-19 vaccine. This vaccine is really helpful for nations with much less sources and who're depending on Johnson & Johnson to struggle the pandemic.
As a result of photographs from Moderna or Pfizer are simpler in opposition to COVID-19 variants equivalent to Omicron and since the Janssen vaccine has been linked to uncommon, however probably deadly blood clots prior to now, wealthier nations just like the U.S. favor them.
It's cheaper than double-dose vaccines, and it's simpler to manage. This makes it extra in style in low-income nations.
Post a Comment